- Home
- ZNB vs VBIO Comparison
ZNB vs VBIO Comparison
Compare ZNB & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNB | VBIO |
|---|---|---|
| Founded | 2002 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4M | 1.6M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZNB | VBIO |
|---|---|---|
| Price | $1.34 | $2.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 314.9K | ★ 6.5M |
| Earning Date | 11-12-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $0.11 |
| 52 Week High | $9.78 | $4.14 |
Technical Indicators
Market Signals| Indicator | ZNB | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 54.90 |
| Support Level | $1.29 | $0.25 |
| Resistance Level | $1.90 | $4.14 |
| Average True Range (ATR) | 0.12 | 0.59 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 0.00 | 50.60 |
Price Performance
Historical ComparisonAbout ZNB Zeta Network Group Class A Ordinary Shares
Zeta Network Group is an entertainment technology company with a network that focuses on the application of technology and artificial intelligence in the entertainment industry. It provides online entertainment performances and online education through its wholly-owned subsidiaries Color Metaverse and CACM. The curriculum developed by the company includes music, sports, animation, painting and calligraphy, film and television, and life skills, covering various aspects of entertainment, sports, and culture.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.